Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06773715 · ClinicalTrials.gov registry record · NA

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

A NA study of Sickle Cell Disease and Vaso-occlusive Pain Episodes, sponsored by Louisiana State University Health Sciences Center in New Orleans.

Recruiting
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT06773715: Recruiting NA study of Sickle Cell Disease and Vaso-occlusive Pain Episodes, sponsored by Louisiana State University Health Sciences Center in New Orleans.

NCT06773715 is a NA study of Sickle Cell Disease and Vaso-occlusive Pain Episodes that is actively recruiting participants, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 36 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06773715, a NA study of Sickle Cell Disease and Vaso-occlusive Pain Episodes, is actively recruiting participants, sponsored by Louisiana State University Health Sciences Center in New Orleans.

RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are: Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis? Does virtual reality decrease the daily use of opiates? Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain. All patients will: \- Be asked to fill out a pain assessment survey three times daily for up to 3 days If randomized to intervention arm, patients will: * Participate in an immersive virtual reality experience once daily for up to 3 days * Fill out a survey twice daily to monitor for side effects from virtual reality experience * Fill out a satisfaction survey once during the study period

Primary Outcome

The Adolescent-Pediatric Pain Tool is a well validated, multidimensional pain assessment tool designed to evaluate the location, severity, and quality of pain in pediatric patients. It is comprised of three independent parts, one which is a 10 cm line anchored from 0 to10, with zero being equivalent to "no pain" and 10 being equivalent to "worst pain possible". This data point will be collected up to 9 times for each participant in this study. The trends will be compared amongst the control and

Interventions

  • DEVICE KindVR Aqua Program

Study Locations (1)

Louisiana

  • Children's Hospital of New Orleans - New Orleans

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2024-09-12
Est. Completion 2025-12-19
Phase NA

What NCT06773715 shows while recruiting

NCT06773715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which KindVR Aqua Program is the first listed.

NCT06773715 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT06773715 about?

NCT06773715 is a clinical study titled "Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain". The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are: Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis? Does virtual rea...

What is the current status of trial NCT06773715?

This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2024-09-12. Estimated completion is 2025-12-19.

What conditions does trial NCT06773715 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes.

What interventions are being tested in trial NCT06773715?

The interventions under investigation include: KindVR Aqua Program (DEVICE).

Who is sponsoring clinical trial NCT06773715?

This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06773715 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06773715's enrollment target sits among peer trials

36 130th of 213 higher than 81 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06773715, the US trial registry maintained by the National Library of Medicine. NCT06773715 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.